Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
With the licensing and subsequent roll-out of female vaccination against human papillomavirus (HPV) in many, mainly high-resource settings, there has emerged a chorus of voices advocating vaccination for males. The interest in male vaccination has intensified with the publication of early observational data from Australia heralding the effectiveness of vaccination when high coverage is achieved1 ,2 and the results of clinical trials demonstrating efficacy against infection and disease in males.3 A recent mathematical modelling study by Brisson et al provides estimates of the potential long-term benefits of HPV vaccination, including the incremental benefit of adding male vaccination to an existing female-only programme.
A previously described4 individual-based transmission-dynamic model was developed and calibrated to sexual behaviour and HPV …
Competing interests DR is the recipient of an Australian Research Council Linkage Project (grant number LP0883831). CSL Ltd is a Partner Organisation on this project. Dr Regan has received honoraria from CSL Ltd.
Note Note Since this commentary was written, the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that males be included in the government funded National HPV Immunisation Program in Australia